bioRxivCancer BiologyPreprint
dbGIST: An LLM-Assisted Multi-Omics Resource for Target Exploration and Cross-Dataset Validation in Gastrointestinal Stromal Tumors
Zhao SuniD, Qian ZhaoiD, Jie-Han Li, Jiajing LiiD, H F LiuiD, Yanxu GuoiD, Yadong TangiD, Fei Yang, Xin LiuiD, San-Fei Peng, Wu-nan Mi, Ge Zhang, Z Z ZhangiD, Yuan Ming-liang, Guanghui LiiD, Yun-Fei Wang, Chao LiuiD, Shenglei LiiD, Jing-Hua YangiD, Yang FuiD
Abstract
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract, yet GIST-specific omics evidence remains scattered across small cohorts and is not represented as a dedicated disease project in major cancer genomics resources, limiting reproducible target exploration. Here, we present dbGIST (https://www.dbgist.com), a dedicated GIST-focused multi-omics resource built to make dispersed GIST evidence searchable, analyzable, and reusable. dbGIST harmonizes data from 37 centers and 1,991 samples, including pathologically verified in-house cohorts, across genomics, bulk transcriptomics, proteomics, phosphoproteomics, and single-cell transcriptomics, and couples these data with curated clinical annotations covering survival, mutation status, risk stratification, metastasis or recurrence, mitotic index, tumor site and size, and imatinib response. The platform supports cohort-level molecular-clinical association, survival, enrichment, immune-infiltration, drug-sensitivity, and single-cell analyses through interactive visualizations, downloadable source data, and public APIs for programmatic access to reusable analysis outputs and visualization-ready data. An optional LLM-assisted interface helps users navigate analyses and interpret outputs. Using MCM7 as a case study, dbGIST linked a resource-derived candidate to survival, risk features, metastatic or recurrent disease, imatinib-response phenotypes, proliferative cell states, and in vitro GIST-cell behavior. dbGIST therefore provides a traceable and interoperable resource for target exploration and precision oncology research in GIST.
- organism: human
- assay: bulk RNA-seq
- assay: proteomics
- assay: metabolomics
- assay: spatial transcriptomics
- research focus: clustering
- research focus: differential expression
- research focus: drug response / drug discovery
- approach: deep learning
- approach: statistical model
- approach: benchmark study
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Liquid biopsy in gastrointestinal stromal tumors -- Simultaneous detection of primary and secondary mutations with an NGS based circulating tumor DNA assay
N. Somasundaram, R. Quek, … S. B. Ng·bioRxiv·Nov 30, 2018
- Systematic elucidation and pharmacologic targeting of non-oncogene dependencies in imatinib-resistant gastrointestinal stromal tumor
Prabhjot Singh Mundi, Adina Grunn, … Andrea Califano·bioRxiv·Oct 12, 2025
- Single Nuclei-Derived Molecular Subtypes of Gastrointestinal Stromal Tumors Correlate with Clinicopathologic Features and Predict Clinical Outcomes
Ashwyn K. Sharma, Alexander T. Wenzel, … Jason Keith Sicklick·bioRxiv·Apr 21, 2025
- Multi-omics reveals AKR1B1-regulated galactose metabolic as a driver of gastrointestinal stromal tumor progression
Xiaonan Yin, Hongxin Yang, … Yuan Yin·bioRxiv·May 21, 2024
- Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data for Chinese Glioma Patients
Zheng Zhao, Kenan Zhang, … Tao Jiang·Genomics Proteomics & BioinformaticsPeer-reviewed·Feb 1, 2021
- Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence
Hadeesha Piyadasa, Benjamin Oberlton, … Michael Angelo·Cancer CellPeer-reviewed·Dec 11, 2025